\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Events

Trovagene Investor Presentation - HC Wainwright Investor Conference
 September 10, 2019 -
December 10, 2019
 10:50am EDT

Dr. Thomas Adams, CEO and Chairman and Dr. Mark Erlander, CSO, will present an overview of Trovagene and the Onvansertib Clinical Development Program at the HC Wainwright Conference in NYC on Tuesday, September 10, at 10:50 am EDT.  The webcast of the presentation will be archived and available for 90 days.